News ArticleSun Pharmaceutical Industries Announces Key Investor Meetings in Mumbai for November 2026
Company to engage with analysts and institutional investors at major conferences including CLSA 29th India Forum and JM Financial India Xchange without disclosing UPSI
Sun Pharmaceutical Industries Limited has announced a schedule of analyst and institutional investor meetings in Mumbai during November 2026, including participation in the CITIC-Securities CLSA 29th India Forum, Avendus Spark INDX Annual Investor Conference, and JM Financial India Xchange 2026. These meetings will be conducted physically and comprise both group and one-on-one sessions without sharing any unpublished price sensitive information.
Sun Pharmaceutical Industries Limited
General / Other
Sun Pharmaceutical Industries Limited has revealed its upcoming schedule of analyst and institutional investor meetings slated for mid-November 2026 in Mumbai. These events include participation in prominent investor forums and will feature both group and individual sessions.
The company will be present at the CITIC-Securities CLSA 29th India Forum 2026 on November 17, hosting both physical group and one-on-one meetings.
On November 18, Sun Pharma will attend the Avendus Spark INDX Annual Investor Conference and the JM Financial India Xchange 2026, continuing the format of physical group and one-on-one interactions.
Sun Pharmaceutical has confirmed adherence to regulatory compliance by not disclosing any Unpublished Price Sensitive Information (UPSI) during these meetings.
The schedule is subject to change depending on exigencies affecting either the company or the event organizers.
Highlights
- Meetings scheduled for November 17 and 18, 2026, in Mumbai.
- Participation in three key investor conferences.
- Format includes both group and one-on-one physical meetings.
- No unpublished price sensitive information will be shared.
- Schedule may be updated based on unforeseen requirements.
Key Data Snapshot
What happened
- Sun Pharmaceutical has announced its schedule for analyst and institutional investor meetings taking place in Mumbai on November 17 and 18, 2026.
- The meetings will include participation at major investor conferences including the CITIC-Securities CLSA 29th India Forum, Avendus Spark INDX Annual Investor Conference, and JM Financial India Xchange 2026.
- Meetings will be conducted physically with options for group discussions and one-on-one sessions.
Key details
- No unpublished price sensitive information will be disclosed during these meetings, ensuring compliance with SEBI regulations.
- The schedule is subject to change depending on emergencies or unforeseen requirements from either the company or the event hosts.
- Company Secretary Anoop Deshpande signed off the disclosure dated 5 November 2026.
Regulatory and governance context
- This disclosure complies with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Sun Pharmaceutical disclosed the meetings to the National Stock Exchange of India and BSE Limited under appropriate filings.
Highlights
- Meetings scheduled for November 17 and 18, 2026, in Mumbai.
- Participation in three key investor conferences.
- Format includes both group and one-on-one physical meetings.
- No unpublished price sensitive information will be shared.
- Schedule may be updated based on unforeseen requirements.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulation 30
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Gujarat Energy Limited Reports Q2 and H1 FY2026 Unaudited Results; Secures 0.8 MTPA LNG Supply Agreement for 10 Years
Gujarat Energy Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a profit after tax of ₹1,637.24 crore for the half year. Additionally, the company secured long-term LNG sourcing agreements totaling approximately 0.8 MTPA for up to 10 years, linked to Henry Hub pricing, and booked regasification capacity at GSPC LNG Limited's Mundra LNG Terminal to ensure a reliable LNG supply.
Read Full Story
Go Digit General Insurance Releases Q2 and H1 FY2026-27 Unaudited Ind AS Financial Results
Go Digit General Insurance announced its unaudited Ind AS financial results for the quarter and half-year ended September 30, 2026, reporting insurance revenue of Rs. 272,049 lakh for the quarter and an insurance service result of Rs. 4,304 lakh for the same period.
Read Full Story
Cholamandalam Financial Holdings Posts Rs.1,520 Cr Consolidated PAT for Q2 FY27, Up 25% Year-on-Year
Cholamandalam Financial Holdings Limited reported a consolidated profit after tax (PAT) of Rs.1,520 crore for the quarter ended September 30, 2026, marking a 25% increase compared to the same quarter last year. Consolidated total income for the quarter grew by 19% to Rs.11,388 crore, reflecting growth across its financial services and insurance subsidiaries.
Read Full Story
